Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DRIO
stocks logo

DRIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
5.10M
-32.98%
-5.340
+233.75%
6.63M
-1.83%
-3.380
+20.71%
8.20M
+52.74%
-3.070
-14.72%
Estimates Revision
The market is revising Downward the revenue expectations for DarioHealth Corp. (DRIO) for FY2025, with the revenue forecasts being adjusted by -6.84% over the past three months. During the same period, the stock price has changed by 25.52%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.84%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-17.85%
In Past 3 Month
Stock Price
Go Up
up Image
+25.52%
In Past 3 Month
Wall Street analysts forecast DRIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRIO is 13.50 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast DRIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRIO is 13.50 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 12.050
sliders
Low
11.00
Averages
13.50
High
16.00
Current: 12.050
sliders
Low
11.00
Averages
13.50
High
16.00
Stifel
David Grossman
Buy
maintain
$16
2025-11-14
Reason
Stifel
David Grossman
Price Target
$16
2025-11-14
maintain
Buy
Reason
Stifel analyst David Grossman adjusted the firm's price target on DarioHealth to $16 from $1.25 and keeps a Buy rating on the shares. While "encouraged" by management's ability to lower expenses and continue to sign meaningful new customer relationships, the firm views the stock as unlikely to regain momentum until there are visible signs of accelerating revenue growth and a path to profitability. Following the 20-1 reverse stock split, the firm notes that its prior price target of $1.25 would have equated to $25.
TD Cowen
Hold
maintain
$11
2025-11-14
Reason
TD Cowen
Price Target
$11
2025-11-14
maintain
Hold
Reason
TD Cowen raised the firm's price target on DarioHealth to $11 from 60c and keeps a Hold rating on the shares. The company updated its model following Q3 results which showed its revenue weakness continuing but noting its strong pipeline could lead to a recovery in 2026.
Stifel
Buy
downgrade
2025-08-13
Reason
Stifel
Price Target
2025-08-13
downgrade
Buy
Reason
Stifel lowered the firm's price target on DarioHealth to $1.25 from $1.50 and keeps a Buy rating on the shares. The firm's projections assume the company has sufficient cash to fund operations through 2025 without accessing its credit line, but the firm contends the stock is unlikely to regain momentum until there are visible signs of accelerating revenue growth and a path to profitability, the analyst tells investors in a post-earnings note.
Litchfield Hills
Theodore O'Neill
Buy
initiated
$3
2025-05-19
Reason
Litchfield Hills
Theodore O'Neill
Price Target
$3
2025-05-19
initiated
Buy
Reason
Stifel
Buy
downgrade
$2
2025-05-14
Reason
Stifel
Price Target
$2
2025-05-14
downgrade
Buy
Reason
Stifel lowered the firm's price target on DarioHealth to $1.50 from $2 and keeps a Buy rating on the shares following a below Q1, reflecting transition of scope with large national health plan and modest impact from downstream tariff-related delays within their partner channel. The firm is lowering 2025 revenue estimate to reflect this dynamic. However, significant contract awards in the last several months should begin ramping in the second half of 2025 and into 2026. Management is still targeting free cash flow breakeven in Q1 2026. While possible, Stifel's estimates are less aggressive. It continues to estimate the company has sufficient cash/borrowing capacity to fund operations through achieving breakeven. While there are still several moving pieces impacting near-term growth, the firm is encouraged by management's ability to lower expenses and continues to sign meaningful new customer relationships.
Stifel
David Grossman
Strong Buy
Maintains
$3.5 → $2
2025-03-11
Reason
Stifel
David Grossman
Price Target
$3.5 → $2
2025-03-11
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for DarioHealth Corp (DRIO.O) is -0.90, compared to its 5-year average forward P/E of -2.20. For a more detailed relative valuation and DCF analysis to assess DarioHealth Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.20
Current PE
-0.90
Overvalued PE
-0.71
Undervalued PE
-3.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.39
Undervalued EV/EBITDA
-4.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.24
Current PS
0.00
Overvalued PS
8.06
Undervalued PS
0.42
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 366.34% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 109.67% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 366.34% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

DRIO News & Events

Events Timeline

(ET)
2025-12-02
08:11:00
DarioHealth Secures 34 New Employer Clients, Exceeding 2025 Target by 98%
select
2025-11-24 (ET)
2025-11-24
08:09:25
DarioHealth Reveals Study Publication in JMIR Regarding Digital Health Platform
select
2025-11-13 (ET)
2025-11-13
06:36:29
DarioHealth announces Q3 EPS of $2.96, surpassing consensus estimate of $2.42
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04Newsfilter
DarioHealth's Digital Nudges Significantly Lower Hypertension Outcomes
  • Significant Clinical Impact: A study published by DarioHealth in JMIR Cardio shows that data-driven digital nudges lead to a statistically significant reduction of 2.09 mmHg in monthly average systolic blood pressure among high BP users three months post-intervention, compared to a 1.06 mmHg reduction in the control group, demonstrating effectiveness in improving cardiovascular health outcomes.
  • Enhanced User Engagement: The research indicates that users with higher lifestyle activity levels achieved a greater systolic blood pressure reduction of 5.27 mmHg, underscoring the additive benefits of combining behavioral engagement with digital nudges, thereby enhancing DarioHealth's competitive position in the market.
  • Cost Savings in Health: By improving hypertension control, DarioHealth's platform has the potential to reduce costs associated with cardiovascular complications, translating into measurable value for employers and healthcare systems while improving overall population health.
  • Long-term Management Capability: The findings suggest that digital interventions are not merely momentary triggers but can support sustained hypertension management, further solidifying DarioHealth's leadership in the digital health space.
[object Object]
Preview
3.5
11-24PRnewswire
DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year

  • Study Findings: A peer-reviewed study by Sanofi and Symphony Health revealed that Dario's digital diabetes intervention platform resulted in 23% lower hospitalization rates and 26% lower healthcare charges compared to usual care for type 2 diabetes patients.

  • Engagement Impact: Increased engagement with the Dario platform was associated with fewer inpatient and emergency room events, highlighting the effectiveness of continuous digital health support.

  • Economic Validation: The study provided strong evidence that digital health interventions can significantly reduce healthcare costs and utilization, addressing key concerns of payers and employers regarding the financial impact of such solutions.

  • DarioHealth Overview: DarioHealth is a digital health company focused on chronic condition management, offering personalized interventions through a user-centric platform that aims to improve health outcomes and reduce costs for users and healthcare systems.

[object Object]
Preview
9.5
11-13NASDAQ.COM
DarioHealth Corp. Reports Reduced Losses in Q3

  • Quarterly Loss: DarioHealth Corp. reported a loss of $10.47 million for the third quarter, improving from a loss of $12.33 million in the same period last year.

  • Earnings Per Share: The company's earnings per share (EPS) were -$2.96, compared to -$4.91 in the previous year.

  • Revenue Decline: Revenue for the quarter decreased by 32.5%, totaling $5.01 million, down from $7.42 million last year.

  • Financial Overview: The financial results indicate a significant reduction in losses year-over-year, despite a notable drop in revenue.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is DarioHealth Corp (DRIO) stock price today?

The current price of DRIO is 12.05 USD — it has increased 1.69 % in the last trading day.

arrow icon

What is DarioHealth Corp (DRIO)'s business?

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

arrow icon

What is the price predicton of DRIO Stock?

Wall Street analysts forecast DRIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRIO is 13.50 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is DarioHealth Corp (DRIO)'s revenue for the last quarter?

DarioHealth Corp revenue for the last quarter amounts to 5.01M USD, decreased -32.55 % YoY.

arrow icon

What is DarioHealth Corp (DRIO)'s earnings per share (EPS) for the last quarter?

DarioHealth Corp. EPS for the last quarter amounts to -2.96 USD, decreased -59.06 % YoY.

arrow icon

What changes have occurred in the market's expectations for DarioHealth Corp (DRIO)'s fundamentals?

The market is revising Downward the revenue expectations for DarioHealth Corp. (DRIO) for FY2025, with the revenue forecasts being adjusted by -6.84% over the past three months. During the same period, the stock price has changed by 25.52%.
arrow icon

How many employees does DarioHealth Corp (DRIO). have?

DarioHealth Corp (DRIO) has 196 emplpoyees as of December 05 2025.

arrow icon

What is DarioHealth Corp (DRIO) market cap?

Today DRIO has the market capitalization of 81.56M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free